The potential of proton beam radiation therapy in lung cancer (including mesothelioma)

References

• Cancer Incidence in Sweden. Epidemiologiskt Centrum 2003; www.sos.se.
   Google Scholar
• Talbäck M, Stenbeck M, Rosén M, Glimelius B. Cancer survival in Sweden. Acta Oncol 2003; 42: 637–59
   PubMed Web of Science ®Google Scholar
• The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer. N Engl J Med 2004;350:351–60.
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Rosell R, Delena M, Legroumellec A, Torres A, Carpagnano F, et al ANITA: Phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (stage I–III) non-small cell lung cancer patients. Final results after 70-month median follow-up. J Clin Oncol 2005;23((Suppl 16S)):624s. abstract.
   Google Scholar
• Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589–97
   PubMed Web of Science ®Google Scholar
• Burdett S, Stewart L. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 2005; 47: 81–3
   PubMed Web of Science ®Google Scholar
• Chahinian AP, Harvey IP. Malignant Mesothelioma. Cancer Medicine, volume 6, JF Holland, E Frei. BC Decker Inc, London 2003; 1447–66
   Google Scholar
• Sirzén F, Kjellen E, Sörenson S, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in non-small cell lung cancer. Acta Oncol 2003; 42: 493–515
   PubMed Web of Science ®Google Scholar
• Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax 2001; 56: 628–38
   PubMed Web of Science ®Google Scholar
• Zimmermann FB, Bamberg M, Molls M, Jeremic B. Radiation therapy alone in early stage non-small cell lung cancer. Semin Surg Oncol 2003; 21: 91–7
   PubMedGoogle Scholar
• Uematsu M, Shioda A, Suda A, Fukui T, Ozeki Y, Hama Y, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001; 51: 666–70
   PubMed Web of Science ®Google Scholar
• Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003; 124: 1946–55
   PubMed Web of Science ®Google Scholar
• Bush DA, Slater JD, Bonnet R, Cheek GA, Dunbar RD, Moyers M, et al. Proton-beam radiotherapy for early-stage lung cancer. Chest 1999; 116: 1313–9
   PubMed Web of Science ®Google Scholar
• Bonnet RB, Bush D, Cheek GA, Slater JD, Panossian D, Franke C, et al. Effects of proton and combined proton/photon beam radiation on pulmonary function in patients with resectable but medically inoperable non-small cell lung cancer. Chest 2001; 120: 1803–10
   PubMed Web of Science ®Google Scholar
• Moyers MF, Miller DW, Bush DA, Slater JD. Methodologies and tools for proton beam design for lung tumors. Int J Radiat Oncol Biol Phys 2001; 49: 1429–38
   PubMed Web of Science ®Google Scholar
• Bush DA, Slater JD, Shin BB, Cheek G, Miller DW, Slater JM. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest 2004; 126: 1198–203
   PubMed Web of Science ®Google Scholar
• Koto M, Miyamoto T, Yamamoto N, Nishimura H, Yamada S, Tsujii H. Local control and recurrence of stage I non-small cell lung cancer after carbon ion radiotherapy. Radiother Oncol 2004; 71: 147–56
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Yamamoto N, Nishimura H, Koto M, Tsujii H, Mizoe JE, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2003; 66: 127–40
   PubMed Web of Science ®Google Scholar
• Lee C, Tait D, Nahum A, Webb S. Comparison of proton therapy and conformal x-ray therapy in non-small cell lung cancer (NSCLC). Br J Radiat 1999; 72: 1078–84
   PubMed Web of Science ®Google Scholar
• Möller TR, Brorsson B, Ceberg J, Frodin JE, Lindholm C, Nylen U, et al. A prospective survey of radiotherapy practice 2001 in Sweden. Acta Oncol 2003; 42: 387–410
   PubMed Web of Science ®Google Scholar
• Fowler JF. What can we expect from dose escalation using proton beams?. Clin Oncol (R Coll Radiol) 2003; 15: S10–5
   PubMed Web of Science ®Google Scholar
• Turrisi AT, 3rd. It's about time, or is it volume, fractionation, or technique? Int J Radiat Oncol Biol Phys 1996;36:753–5.
   PubMed Web of Science ®Google Scholar
• Liengswangwong V, Bonner JA. Point: the potential importance of elective nodal irradiation in the treatment of non-small cell lung cancer. Semin Radiat Oncol 2000; 10: 308–14
   PubMed Web of Science ®Google Scholar
• Forssell-Aronsson E, Kjellén E, Mattsson S, Hellström M. and the Swedish Cancer Society Investigation Group. Medical imaging for improved tumour characterisation, delineation and treatment verification. Acta Oncol 2002;41:604–14.
   PubMed Web of Science ®Google Scholar
• Black QC, Grills IS, Kestin LL, Wong CY, Wong JW, Martinez AA, et al. Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys 2004; 60: 1272–82
   PubMed Web of Science ®Google Scholar
• Brahme A. Biologically optimized 3-dimensional in-vivo predictive assay based radiation therapy using PET-CT imaging. Acta Oncol 2003; 42: 123–36
   PubMed Web of Science ®Google Scholar
• Svensson H, Möller T. Developments in radiotherapy. Acta Oncol 2003; 42: 430–42
   PubMed Web of Science ®Google Scholar
• Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6: 527–35
   PubMed Web of Science ®Google Scholar